Welcome to the
Hospital Administrator Section
CTCL and the THERAKOS™ Photopheresis System
This Web site is designed to assist hospital administrators by providing information and a variety of resources for THERAKOS™ Photopheresis and CTCL.
Important Safety Information
Indications
UVADEX® (methoxsalen) Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR™XTS™ or THERAKOS™ CELLEX™ Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen should be used only by physicians who have special training in the THERAKOS™ UVAR™ XTS™ or THERAKOS™ CELLEX™ Photopheresis Systems. Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions to psoralen compounds, patients with a specific history of a light sensitive disease, or patients with aphakia.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate extracorporeal volume loss or shifts, or patients with coagulation disorders. See Important Safety Information for additional details.
You’ll find the following sections on this Web site:
What is CTCL?
An introduction to CTCL, its symptoms, diagnosis, and treatment
About THERAKOS™ Photopheresis
An overview that addresses many of the questions we’re sure you will have
Experiencing THERAKOS™ Photopheresis
Stories from people who have had the treatment and have shared their experiences
Reimbursement Issues
Therakos, Inc. can help
Hospital Administrators
Information and downloadable materials for Administrators